HRA Pharma is attending this year’s European Congress of Endocrinology in Berlin, Germany.

If you wish to meet with us during this event, please contact us at:
info@hra-pharma. or come and visit us at the International Congress Centrum ICC Berlin, on our stand n° 8 (www.ece2008.com)

HRA Pharma enters licensing agreement with PregLem to develop and commercialise ulipristal for gynecological disorders.
HRA Pharma announced today that it has entered into a licensing agreement with PregLem, a Swiss specialty biopharmaceutical company, for the European development and commercialisation of HRA Pharma’s selective progesterone receptor modulator, ulipristal, for the treatment of various benign gynecological disorders

  Read more…

Being aware that humanitarian programs should not be restricted to the company's area of business, and because cultural development is a necessity for development, HRA has sponsored an award at the "Rencontres africaines de la photographie" aimed to reward the work of a young African photographer who displays unique talent and a potential for excellence.

  Read more…

HRA Pharma is sponsoring the “Afrique en créations” prize aimed to reward the work of a young, talented African photographer.

  Read more…

HRA Pharma is attending this year’s BIO-Europe International Partnering Conference in Hamburg.

If you wish to meet with us during this event, please contact us at:
info@hra-pharma.

HRA Pharma is attending this year’s International Pharma Licensing Symposium in Berlin.

If you wish to meet with us during this event, please contact us at:
info@hra-pharma.

HRA Pharma commences UK-based Phase III trial of Ella^®, a second-generation emergency contraceptive

HRA Pharma today announced recruitment has begun into a UK-based pivotal Phase III study to evaluate the Company's second-generation emergency contraceptive, Ella^®. The study will be conducted across nine NHS family planning clinics in the UK.

HRA Pharma invest an additional € 2.5 M in cell therapy through its subsidiary Celogos

HRA Pharma, a private pharmaceutical company focused on innovative treatments in women's health and endocrinology, announced today that it has invested a further €2.5 M in its subsidiary Celogos. The funds will allow the French biotech company, a pioneer in the development of cell-based therapies for muscle disorders, to ramp up the on-going clinical development of its pipeline.

HRA Pharma commences US Phase III trial of second-generation emergency contraceptive

HRA Pharma today announced the start of a pivotal multi-centre Phase III study evaluating its proprietary second-generation emergency contraceptive – Ella^®. The study will be conducted in sixteen clinics affiliated with Planned Parenthood Federation of America (PPFA) in seven different US states.